Europe Dispatch Sunday, 22 November 2026
Europe Dispatch

Policy·European Union

EMA committee backs seven new medicines and eleven indication extensions

The European Medicines Agency's CHMP recommended seven medicines for approval at its November 2026 meeting, along with eleven indication extensions, and confirmed two refusals.

A selection of pills to relate to EMA's work
A selection of pills to relate to EMA's work European Medicines Agency (www.ema.europa.eu)
Share on X WhatsApp

The European Medicines Agency's Committee for Medicinal Products for Human Use backed seven medicines for approval at its November 2026 meeting, the agency reported. Each recommended new medicine is pending a European Commission decision.

Aumseqa (aumolertinib) was recommended for a marketing authorisation to treat non-small cell lung cancer, according to the EMA.

Baxfendy (baxdrostat) was recommended for authorisation to treat hypertension that is insufficiently controlled.

Zybrivo (sintilimab) received a positive opinion for treating non-squamous non-small cell lung cancer in adults.

Two biosimilars, Garzulys and Donrafylix, both insulin aspart, received positive opinions for diabetes in adults, adolescents and children aged 1 year and above.

Fondaparinux sodium Evumed, a generic, received a positive opinion for preventing venous thromboembolic events and treating DVT, pulmonary embolism, unstable angina and myocardial infarction in adults.

Ruxolitinib Krka, a generic, received a positive opinion for myelofibrosis and polycythaemia vera in adults and Graft-versus-host disease in adults and children.

The committee recommended extending Gazyvaro (obinutuzumab) to adults with moderate-to-severe active systemic lupus erythematosus. Gazyvaro is said to help patients whose disease standard treatment does not adequately control, lowering disease activity and letting them cut corticosteroid use and related side-effect risk.

Isturisa (osilodrostat) received a positive opinion to extend its use to endogenous Cushing's syndrome in adolescents and children aged 6 years and older.

Indication extensions were recommended for nine more EU-authorised medicines: Bexsero, Cosentyx, Dovato, Enflonsia, Steglatro, Sunlenca, Talzenna, Tivicay and Welireg.

A new 100mg strength of Dapivirine Vaginal Ring was recommended, letting women 16 and older replace it every three months instead of monthly. The ring was assessed under the EU-M4All procedure, with experts from the World Health Organization and regulators from Kenia, South Africa and Zambia taking part.

After re-examination, the CHMP confirmed its refusal recommendation for KemSu (sufentanil / ketamine), intended for acute pain in children and adolescents. It also confirmed refusal for Meplyffa (arimoclomol citrate), for Niemann-Pick disease type C in patients aged two and older, combined with miglustat.

Two initial marketing authorisation applications were withdrawn: Amlypave (anselamimab) for kappa light chain amyloidosis and Qezzaqar (catequentinib) for two soft tissue sarcoma types.

The CHMP issued a communication on Mounjaro (tirzepatide) possibly affecting how reliable oral contraceptives are. The communication says little is known about tirzepatide's effect on oral contraceptive pharmacokinetics and efficacy in women with obesity, overweight or type 2 diabetes. Women using oral contraceptives are now advised either to add a barrier method for 4 weeks after starting tirzepatide and after every dose increase, or to change to a non-oral contraceptive. Following a European Commission decision, the marketing authorisation holder will send the communication to healthcare professionals, and it will be published on the EMA website and in national registers.

November 2026 figures show 7 positive opinions on new medicines, made up of 3 non-orphan, 2 biosimilar and 2 generic/hybrid, with 0 negative opinions, 11 indication extensions and 2 withdrawn applications. Cumulative 2026 totals stand at 79 positive opinions on new medicines, 8 negative opinions, 108 indication extensions and 12 withdrawn applications.

The November 2026 CHMP meeting agenda is published, and minutes are due in the coming weeks, the EMA said.